GPR37
Reaktivität: Human
Wirt: Kaninchen
Polyclonal
FITC
Applikationshinweise
ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
GPR37
(G Protein-Coupled Receptor 37 (Endothelin Receptor Type B-Like) (GPR37))
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known, however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function. Panneuronal expression of Parkin substrate Pael-R causes age-dependent selective degeneration of Drosophila dopaminergic (DA) neurons, coexpression of Parkin degrades Pael-R and suppresses its toxicity.Synonyms: ETBR-LP-1, Endothelin B receptor-like protein 1, G-protein coupled receptor 37, PAELR, Parkin-associated endothelin receptor-like receptor